Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?

Simply Wall St.

Mar 28

Wondering if Scholar Rock Holding at US$42.60 is still priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might imply about value. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2622038252"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622038252\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622038252?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-28 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622038252","market":"hk","top_or_hot":-1,"title":"Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Scholar Rock Holding at US$42.60 is still priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might imply about value. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/is-scholar-rock-holding-srrk-still-attractive-after-recent-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 23:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/is-scholar-rock-holding-srrk-still-attractive-after-recent-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Scholar Rock Holding at US$42.60 is still priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might imply about value. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/is-scholar-rock-holding-srrk-still-attractive-after-recent-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/is-scholar-rock-holding-srrk-still-attractive-after-recent-s","article_id":"2622038252","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/is-scholar-rock-holding-srrk-still-attractive-after-recent-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622038252","pubTimestamp":1774710837,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Scholar Rock Holding at US$42.60 is still priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might imply about value.\nThe stock has given investors a 29.7% return over the last 1 year. More recently the share price shows a 4.6% decline over 7 days and a 9.3% decline over 30 days, with the year to date move close to flat at a 0.5% decline.\nThese mixed returns sit against a backdrop where investors are watching the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","SRRK":"Scholar Rock Holding Corp"},"translate_title":"近期股价回调后，Scholar Rock Holding(SRRK)仍有吸引力吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":1.5,"DCF":1},"content_text":"Wondering if Scholar Rock Holding at US$42.60 is still priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might imply about value. The stock has given investors a 29.7% return over the last 1 year. More recently the share price shows a 4.6% decline over 7 days and a 9.3% decline over 30 days, with the year to date move close to flat at a 0.5% decline. These mixed returns sit against a backdrop where investors are watching the company for updates that could influence expectations around its prospects and risk profile. Recent coverage has focused on how sentiment can shift quickly in this part of the market, which can feed into sharp moves both up and down. Scholar Rock Holding currently has a valuation score of 3 out of 6. The rest of this article will compare what different valuation methods suggest about the stock while also pointing to a more complete way to think about value at the end.  Scholar Rock Holding delivered 29.7% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Scholar Rock Holding Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model looks at the cash the business is expected to generate in the future and then discounts those projected cash flows back to today to estimate what the company might be worth now. For Scholar Rock Holding, the latest twelve month free cash flow is a loss of $300.64 million. Analysts provide free cash flow estimates out to 2030, with Simply Wall St extrapolating further to create a 2 Stage Free Cash Flow to Equity model. In this set of projections, free cash flow is expected to move from negative figures in the near term to $235.67 million in 2030, with later years based on extrapolated estimates rather than direct analyst forecasts. Bringing all of those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $176.23 per share. Compared with the current share price of $42.60, this implies the stock is 75.8% undervalued based on these assumptions and inputs. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Scholar Rock Holding is undervalued by 75.8%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks. SRRK Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Scholar Rock Holding. Approach 2: Scholar Rock Holding Price vs Book For profitable companies that already have an established asset base, the price to book, or P/B, ratio is a common way to think about what investors are paying for each dollar of net assets. A higher multiple usually lines up with stronger growth expectations and lower perceived risk, while slower growth or higher uncertainty tends to justify a lower, more conservative multiple. Scholar Rock Holding currently trades on a P/B ratio of 19.94x. That sits well above the Biotechs industry average P/B of 2.24x and also above the peer group average of 10.28x, so the market is assigning a much richer valuation to its book value than these benchmarks. Simply Wall St’s Fair Ratio concept aims to refine this comparison by estimating what a more tailored P/B multiple could look like once factors such as earnings growth profile, industry, profit margin, market capitalization and key risks are taken into account. This approach can offer a more rounded reference point than relying only on peers or sector averages, which do not fully adjust for company specific characteristics. As the Fair Ratio figure is not available here, it is not possible to say whether the current 19.94x P/B suggests Scholar Rock Holding is overvalued, undervalued or about right on this metric alone. Result: ABOUT RIGHT NasdaqGS:SRRK P/B Ratio as at Mar 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Scholar Rock Holding Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your own story for Scholar Rock Holding that links what you think about apitegromab, the neuromuscular pipeline, regulatory timing and launch execution to a clear set of revenue, earnings and margin estimates. These then roll into a fair value that you can compare with the current price to decide whether the stock looks attractive or stretched for you personally. All of this is available within an easy tool on Simply Wall St’s Community page that updates automatically when new information such as trial results or earnings is released. One investor might build a Narrative that leans closer to the higher analyst fair value of US$70.00 based on confidence in broad SMA and FSHD uptake and the wider anti myostatin platform. Another might sit nearer the lower US$47.00 end if they see more risk around approvals, real world outcomes and the cost of building a 50 country commercial footprint. Do you think there's more to the story for Scholar Rock Holding? Head over to our Community to see what others are saying! NasdaqGS:SRRK 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}